



NOTICE OF TRADING UPDATE

Released : 02 Mar 2018 07:00

RNS Number : 4736G

Amryt Pharma PLC

02 March 2018

2 March 2018

AIM: AMYT

ESM: AYP

**Amryt Pharma plc
("Amryt" or the "Company")**

Notice of Trading Update

Amryt, a biopharmaceutical company focused on rare and orphan diseases, will announce an update on trading on Thursday, 15 March 2018.

The Company will be holding an analyst briefing on the afternoon of the update. For further information, please contact KTZ Communications on 020 3178 6378.

Enquiries:

Amryt Pharma plc

Joe Wiley, CEO

Rory Nealon, CFO/COO

C/o KTZ Communications (details below)

Shore Capital

+44 (0) 20 7408 4090

Nomad and Joint Broker

Edward Mansfield, Mark Percy

Davy

+353 (1) 679 6363

ESM Adviser and Joint Broker

John Frain, Anthony Farrell

Stifel

+44 (0) 20 7710 7600

Joint Broker

Jonathan Senior, Ben Maddison

KTZ Communications

+44 (0) 20 3178 6378

Katie Tzouliadis, Irene Bermont-Penn, Emma Pearson

About Amryt Pharma plc

www.amrytpharma.com

Amryt Pharma is a specialty biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, proprietary new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.

The Company holds an exclusive licence to sell Lojuxta (lomitapide) for adults, across the European Economic Area, Middle East and North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia, which impairs the body's ability to remove LDL cholesterol ("bad" cholesterol) from the blood. This typically results in extremely high blood LDL cholesterol levels, leading to aggressive and premature narrowing and blocking of arterial blood vessels. If left untreated, heart attack or sudden death may occur in childhood or early adulthood.

Amryt's lead drug candidate, AP101, is a potential treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. It is currently in Phase 3 clinical trials. The global market opportunity for EB is estimated to be in excess of EUR 1.3 billion.

Amryt's earlier stage product AP102 is focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing's disease.

The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.

This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCJBMTTMBJMTPP